Baidu
map

Clin Oral Investig:研究揭示CHI3L1在特应性皮炎发生和进展中的作用

2020-09-29 MedSci原创 MedSci原创

特应性皮炎(AD)是一种以皮肤屏障缺陷和Th2免疫反应为特征的慢性炎症性皮肤病。壳蛋白酶3-样 1(CHI3L1),在小鼠中也被称为乳腺回归蛋白39(BRP-39)和人类同源物YKL-40,在Th2炎

特应性皮炎(AD)是一种以皮肤屏障缺陷和Th2免疫反应为特征的慢性炎症性皮肤病。壳蛋白酶3-样 1(CHI3L1),在小鼠中也被称为乳腺回归蛋白39(BRP-39)和人类同源物YKL-40,在Th2炎症和过敏原致敏中发挥重要作用。CHI3L1参与多种疾病中,包括以炎症、细胞凋亡和组织重塑为特征的哮喘,但其在AD中的作用尚未明了。本研究旨在探究CHI3L1在AD的发生和进展中的作用,其研究结果已在线发表于Clin Oral Investig。

我们通过ELISA和免疫荧光法分别调查了AD患者血清和皮肤中YKL-40的水平。以卵清蛋白(OVA)诱导的小鼠AD模型为研究对象,采用野生型(WT)和BRP-39无效突变(BRP-39-/-)小鼠,研究Th2免疫反应、M2巨噬细胞活化和皮肤屏障基因表达。

 

结果显示,AD患者血清中YKL-40水平显著升高。此外,OVA致敏WT小鼠中BRP-39的mRNA和蛋白表达水平均高于对照组小鼠。OVA敏感化BRP-39-/-小鼠的表皮厚度、血清总IgE、Th2细胞因子水平和CD4+效应T细胞数量均低于OVA敏感化WT小鼠。BRP-39的诱导在真皮巨噬细胞中占主导地位。BRP-39的缺失参与了M2巨噬细胞的激活。与此相同的是,AD患者皮肤中YKL-40水平高于正常人,且在真皮巨噬细胞中表达。BRP-39的缺失减轻了皮肤屏障和紧结基因的失调。

 

综上所述,这些研究结果表明,CHI3L1介导OVA诱导的AD的发展,影响Th2炎症、M2巨噬细胞活化和皮肤屏障功能。

 

原始出处:

 

Luigi CanulloTullio Genova, et al., Effects of argon plasma treatment on the osteoconductivity of bone grafting materials. Clin Oral Investig. 2020 Aug;24(8):2611-2623. doi: 10.1007/s00784-019-03119-0. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1234072, encodeId=815112340e2e6, content=老师好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=425e6162698, createdName=ms1000001760263343, createdTime=Fri Jul 22 20:55:35 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051066, encodeId=4fc61051066da, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 11:25:13 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020655, encodeId=c34b20206556c, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Dec 31 10:28:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051609, encodeId=ddda205160972, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 13:28:36 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889314, encodeId=938d88931486, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Sep 29 23:55:16 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2022-07-22 ms1000001760263343

    老师好!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1234072, encodeId=815112340e2e6, content=老师好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=425e6162698, createdName=ms1000001760263343, createdTime=Fri Jul 22 20:55:35 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051066, encodeId=4fc61051066da, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 11:25:13 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020655, encodeId=c34b20206556c, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Dec 31 10:28:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051609, encodeId=ddda205160972, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 13:28:36 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889314, encodeId=938d88931486, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Sep 29 23:55:16 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1234072, encodeId=815112340e2e6, content=老师好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=425e6162698, createdName=ms1000001760263343, createdTime=Fri Jul 22 20:55:35 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051066, encodeId=4fc61051066da, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 11:25:13 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020655, encodeId=c34b20206556c, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Dec 31 10:28:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051609, encodeId=ddda205160972, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 13:28:36 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889314, encodeId=938d88931486, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Sep 29 23:55:16 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2020-12-31 小几洁
  4. [GetPortalCommentsPageByObjectIdResponse(id=1234072, encodeId=815112340e2e6, content=老师好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=425e6162698, createdName=ms1000001760263343, createdTime=Fri Jul 22 20:55:35 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051066, encodeId=4fc61051066da, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 11:25:13 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020655, encodeId=c34b20206556c, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Dec 31 10:28:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051609, encodeId=ddda205160972, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 13:28:36 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889314, encodeId=938d88931486, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Sep 29 23:55:16 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1234072, encodeId=815112340e2e6, content=老师好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=425e6162698, createdName=ms1000001760263343, createdTime=Fri Jul 22 20:55:35 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051066, encodeId=4fc61051066da, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 11:25:13 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020655, encodeId=c34b20206556c, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Dec 31 10:28:36 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051609, encodeId=ddda205160972, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 13:28:36 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889314, encodeId=938d88931486, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Sep 29 23:55:16 CST 2020, time=2020-09-29, status=1, ipAttribution=)]
    2020-09-29 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

FDA接受Tralokinumab治疗中重度特应性皮炎的BLA

Tralokinumab治疗中度至重度特应性皮炎的生物制剂许可申请(BLA)已获美国FDA的批准。

J Allergy Clin Immunol:尼莫利珠单抗可快速持续改善特应性皮炎患者的皮肤炎症和瘙痒症状

尼莫利珠单抗靶向特应性皮炎(AD)中的IL-31受体α亚单位。本研究旨在评估奈莫利珠单抗在AD患者中的新用药策略。

Lancet:abrocitinib单药用于中重度特应性皮炎的治疗

对于青少年和成人中度至重度特应性皮炎患者,每日一次口服abrocitinib是有效且耐受性良好的

JAK抑制剂Rinvoq治疗特应性皮炎:III期临床疗效显著

接受15mg/30mg两种剂量Rinvoq治疗的患者,皮肤清除率和瘙痒减轻比例明显增加,分别有60%和73%的患者达到EASI 75,而安慰剂组为13%。

国家药监局批准非激素外用PDE4抑制剂舒坦明(克立硼罗)用于特应性皮炎治疗

辉瑞(Pfizer)近日宣布,中国国家药品监督管理局(NMPA)已正式批准舒坦明(克立硼罗)2%软膏剂的进口药品注册证。舒坦明在中国被批准用于2岁及以上轻度至中度特应性皮炎(AD)患者的局部外用治疗。

J Invest Dermatol:Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性

Dupilumab是一种白细胞介素-4受体α的全人抗体,可改善中度至重度特应性皮炎(AD)的症状和体征。一项双盲、安慰剂对照研究旨在确定杜匹鲁单抗对皮肤上金黄色葡萄球菌定植和微生物多样性的

Baidu
map
Baidu
map
Baidu
map